“Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article”, ADMET DMPK, vol. 13, no. 5, p. 2956, Oct. 2025, doi: 10.5599/admet.2956.